Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IMA203CD8

Cell therapy · Kills target cells · developed by Immatics US

Phase 1/2 Most advanced trial
IMTX Developer
1 Registered trials

What is IMA203CD8?

IMA203CD8 is a cell therapy made of autologous T cells selected as CD3+CD8+ HLA-Dextramer+ cells, dosed by body surface area. It is studied in adult patients with refractory or recurrent solid tumors and other cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Kills target cells
Therapy area
Oncology
Developer
Immatics US, Inc. (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03686124 Phase 1/2 Refractory Cancer Recruiting IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerRecurrent CancerRefractory CancerSolid Tumor, Adult

More from Immatics US

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind IMA203CD8

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.